Theravance Biopharma, Inc. (NASDAQ:TBPH – Get Rating) has been assigned an average recommendation of “Hold” from the ten brokerages that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, six have given a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $10.19.
TBPH has been the subject of several research analyst reports. HC Wainwright lifted their price objective on Theravance Biopharma from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, February 24th. Morgan Stanley lifted their price target on Theravance Biopharma from $10.00 to $11.00 and gave the stock an “underweight” rating in a research note on Wednesday, March 2nd. Finally, StockNews.com began coverage on Theravance Biopharma in a research note on Thursday, March 31st. They set a “hold” rating for the company.
Several large investors have recently made changes to their positions in the company. Rhumbline Advisers raised its position in shares of Theravance Biopharma by 2.8% in the 4th quarter. Rhumbline Advisers now owns 62,531 shares of the biopharmaceutical company’s stock worth $691,000 after acquiring an additional 1,682 shares in the last quarter. California State Teachers Retirement System raised its position in shares of Theravance Biopharma by 2.7% in the 3rd quarter. California State Teachers Retirement System now owns 75,440 shares of the biopharmaceutical company’s stock worth $558,000 after acquiring an additional 1,983 shares in the last quarter. Swiss National Bank increased its position in Theravance Biopharma by 1.9% during the 4th quarter. Swiss National Bank now owns 121,342 shares of the biopharmaceutical company’s stock valued at $1,341,000 after buying an additional 2,300 shares in the last quarter. Arizona State Retirement System increased its position in Theravance Biopharma by 20.8% during the 3rd quarter. Arizona State Retirement System now owns 14,705 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 2,531 shares in the last quarter. Finally, Deutsche Bank AG increased its position in Theravance Biopharma by 7.7% during the 3rd quarter. Deutsche Bank AG now owns 40,101 shares of the biopharmaceutical company’s stock valued at $297,000 after buying an additional 2,863 shares in the last quarter. 81.80% of the stock is owned by hedge funds and other institutional investors.
Theravance Biopharma (NASDAQ:TBPH – Get Rating) last posted its quarterly earnings data on Wednesday, February 23rd. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.13). The company had revenue of $14.95 million during the quarter, compared to the consensus estimate of $15.59 million. During the same period last year, the company earned ($0.92) earnings per share. As a group, analysts anticipate that Theravance Biopharma will post 0.54 EPS for the current year.
Theravance Biopharma Company Profile (Get Rating)
Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.
- Get a free copy of the StockNews.com research report on Theravance Biopharma (TBPH)
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.